Sign in
CompletedPhase 2

Methylphenidate in Childhood Apraxia of Speech

Key facts

Who runs it
Murdoch Childrens Research Institute
Where
Australia1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
18 people enrolled
Started
14 Mar 2022
Ended
27 Oct 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Methylphenidate Hydrochloride
  • Placebo
Record updated
13 October 2026

Who can take part

Age
6 years to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Has childhood apraxia of speech
  • Aged 6-12 years
  • Can perform the speech tasks for the trial (able to speak single words and short sentences)
  • English as a first language
  • Has adequate hearing
  • Has a legally acceptable representative capable of understanding the informed consent document and providing consent on their behalf
  • Passes the health and medical examination including examination of heart rate and blood pressure for age and weight norms
  • Can commit to the time requirements of the trial
  • Lives within 250 kilometres of the study site (MCRI)
  • Able to swallow a capsule
  • Scores 13 or more out of 27 on either the inattention and/or hyperactivity subscales of the SNAP-IV Parent 18-Item Rating Scale, suggesting clinically significant symptoms of inattention and/or hyperactivity

Who cannot take part

  • Has a diagnosis of severe intellectual disability, or other significant neurodevelopmental conditions (e.g., Fragile X, Down Syndrome, etc.)
  • Has epilepsy or other seizure disorders
  • Is taking medication(s) for another health condition(s) that is known to interfere with MPH
  • Has any contraindication to the stimulant (methylphenidate) medication, including severe anxiety, depression, severe Tourette syndrome, glaucoma, psychotic symptoms, hypertension, congenital heart disease, known past or present diagnosed substance abuse or dependence
  • Is unable to commit to the time requirements of the trial (8 weeks + 2 days)
  • Has a score of moderate or high risk of suicidality, assessed with the Columbia Suicidality Severity Rating Scale (C-SSRS)
  • Has used psychostimulants within the past 3 months (e.g., Ritalin, Concerta, Focalin)
  • Lives more than 250 kilometres from the study site
  • Unable to swallow a capsule

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.

The 2 groups in the trial

  • Sequence A: Methylphenidate, PlaceboTreatment being tested

    Participants will first receive methylphenidate capsules twice daily for four weeks. Doses will be administered four hours apart. The maximum dose is determined based on the participant's weight. After a 2-day washout, participants then receive Placebo (matching methylphenidate capsules) twice daily for four weeks.

    Treatment: Methylphenidate Hydrochloride and Placebo

  • Sequence B: Placebo, MethylphenidateTreatment being tested

    Participants will first receive Placebo capsules twice daily for four weeks. Doses will be administered four hours apart. After a 2-day washout, participants then receive methylphenidate capsules (matching Placebo capsules) twice daily for four weeks. The maximum dose is determined based on the participant's weight.

    Treatment: Methylphenidate Hydrochloride and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial
Record updated
13 October 2026